Aurobindo and MSN set to lose US patent protection for Nuplazid in August 2038
A recent US district court ruling has brought relief to Acadia Pharmaceuticals, the manufacturer of Nuplazid, a medication used to treat hallucinations and delusions associated with Parkinson’s disease psychosis. The court’s decision has upheld the validity of a key formulation patent for Nuplazid, which is set to expire in August 2038. This ruling means that generic versions of the medication, including one developed by Aurobindo, will not be able to enter the market until the patent expires.
The court found that Aurobindo’s abbreviated new drug application (ANDA) for a generic version of Nuplazid infringed on Acadia’s patent. Furthermore, the court also ruled that MSN, another company, had already admitted to infringing on the patent. This decision is a significant victory for Acadia, as it protects the company’s exclusive rights to market Nuplazid in the US for several more years.
The ruling is also a blow to generic drug manufacturers, who had been seeking to enter the market with their own versions of Nuplazid. Aurobindo and other companies had been trying to capitalize on the growing demand for treatments for Parkinson’s disease psychosis, which is a significant and underserved market. However, with the court’s decision, these companies will now have to wait until the patent expires in 2038 before they can launch their own generic versions.
The decision is also a testament to the strength of Acadia’s patent portfolio and the company’s ability to defend its intellectual property. Acadia has invested heavily in developing Nuplazid, and the medication has become a key driver of the company’s growth. The court’s ruling ensures that Acadia will be able to continue to reap the benefits of its investment in Nuplazid for several more years.
Overall, the court’s decision is a significant development in the pharmaceutical industry, and it highlights the importance of intellectual property protection in the development of new medications. With the patent for Nuplazid set to expire in 2038, Acadia will have a significant amount of time to continue to market and sell the medication before generic competition enters the market. This will provide the company with a stable source of revenue and allow it to continue to invest in the development of new treatments for Parkinson’s disease and other conditions.
SK bioscience wins Pfizer vaccine patent case: Investing.com India reports
South Korea’s SK bioscience has emerged victorious in a patent lawsuit against Pfizer, concerning the pneumococcal vaccine. The company won the backing of the Korean Supreme Court, bringing an end to the long-standing dispute. The court’s decision confirms that SK bioscience did not infringe on Pfizer’s patent for the pneumococcal conjugate vaccine, Prevnar 13.
The pneumococcal vaccine is used to protect against infections caused by Streptococcus pneumoniae, a bacterium that can cause diseases such as pneumonia, meningitis, and sepsis. Prevnar 13, developed by Pfizer, is a widely used pneumococcal conjugate vaccine that protects against 13 different serotypes of the bacteria.
SK bioscience had developed its own pneumococcal conjugate vaccine, which was found to not infringe on Pfizer’s patent. The company had argued that its vaccine uses a different conjugation method and does not employ the same technology as Prevnar 13. The Korean Supreme Court’s ruling supports SK bioscience’s claim, stating that the company’s vaccine does not violate Pfizer’s patent rights.
The victory is significant for SK bioscience, as it allows the company to continue developing and marketing its pneumococcal conjugate vaccine without the threat of patent infringement. The ruling also underscores the importance of innovation and competition in the pharmaceutical industry, as companies like SK bioscience work to develop new and improved vaccines to protect public health.
The decision is also seen as a major win for the Korean biotech industry, demonstrating the country’s growing capabilities in the field of vaccine development. SK bioscience is one of the leading biotech companies in Korea, and its success in the patent lawsuit against Pfizer is expected to boost the company’s reputation and credibility in the global market.
Overall, the outcome of the patent lawsuit is a positive development for SK bioscience, the Korean biotech industry, and the global effort to develop and distribute effective vaccines. With the ruling, SK bioscience can continue to focus on its mission to develop innovative vaccines and contribute to the protection of public health worldwide.
Today’s Earnings Schedule: Q4 Results from Hindalco, Dixon Tech, Zydus Life, and Torrent Pharma Released – Expert Earnings Projections
Several Indian companies are set to announce their fourth-quarter results on Tuesday, including Hindalco Industries Ltd., Dixon Technologies (India) Ltd., Zydus Lifesciences Ltd., and Torrent Pharmaceuticals Ltd. According to consensus analysts’ estimates compiled by Bloomberg, here’s what can be expected from each company:
Hindalco Industries Ltd. is expected to report a 6% increase in consolidated revenue, reaching Rs 59,251 crore. The company’s estimated Earnings Before Interest, Taxes, Depreciation, and Amortization (Ebitda) is Rs 8,048 crore, with a margin of 13.6%. The net profit is forecasted to be Rs 3,555 crore.
Dixon Technologies (India) Ltd. is anticipated to report revenue of Rs 10,748 crore, with an Ebitda of Rs 403 crore and a margin of 3.7%. The company’s net profit is expected to be Rs 217 crore.
Zydus Lifesciences Ltd. is expected to report revenue of Rs 6,434 crore, with an Ebitda of Rs 2,026 crore and a margin of 31.5%. The company’s net profit is forecasted to be Rs 1,370 crore.
Torrent Pharmaceuticals Ltd. is estimated to report revenue of Rs 2,988 crore, with an Ebitda of Rs 981 crore and a margin of 32.8%. The company’s net profit is expected to be Rs 524 crore.
These estimates suggest that all four companies are expected to report significant revenue and profit growth in the fourth quarter. Hindalco’s revenue growth is expected to be driven by a rebound in demand for aluminum and copper products. Dixon Technologies’ revenue growth is expected to be driven by an increase in demand for electronic products. Zydus Lifesciences and Torrent Pharmaceuticals are expected to benefit from a strong performance in the pharmaceutical sector.
Overall, the fourth-quarter results of these companies are expected to provide insights into the performance of various industries, including metals, electronics, and pharmaceuticals. The results will also be closely watched by investors and analysts to gauge the impact of various macroeconomic factors on the companies’ performance.
Gujarat’s Vyara Civil Hospital shift to PPP model Spells Agony for Tribals and Patients
In 2020, the NITI Aayog recommended that state governments hand over the management of public hospitals to private players. However, the Gujarat government had already taken this step in 2009, when it privatized the Bhuj Civil Hospital, which was rebuilt after the 2001 earthquake at a cost of Rs 100 crore from the Prime Minister’s Relief Fund. The hospital was handed over to the Adani Foundation on a 99-year lease under a Public-Private Partnership (PPP) model. The hospital was renamed the G.K. General Hospital and integrated with the Gujarat Adani Institute of Medical Sciences (GAIMS), which offers undergraduate and postgraduate courses in medicine.
Since then, the Gujarat government has privatized two more hospitals, the Dahod Civil Hospital, which was handed over to the Zydus Group in 2017, and the Vyara Civil Hospital, which was initially supposed to be handed over to the Torrent Group but was met with protests and has now been taken over by the UNM Foundation, a non-profit arm of the Torrent Group. The privatization of these hospitals has been mired in controversies, with allegations of exorbitant fees being charged to patients, poor treatment, and high infant and child mortality rates.
For instance, between January and May 2018, over 110 newborn babies died at the G.K. General Hospital, and in 2019, the hospital was accused of charging high fees for outpatient department (OPD) treatments, which were previously free. The hospital has also been criticized for the high fees charged for undergraduate and postgraduate courses, with the fee for a five-year MBBS program ranging from Rs 29-43 lakh for government and NRI quota seats, and Rs 80.5 lakh for management quota seats.
Similarly, the Zydus Medical College and Hospital charges Rs 6.85 lakh per year for 132 government quota PG seats, Rs 15 lakh a year for management quota seats, and Rs 19.5 lakh each for the 23 NRI seats. In contrast, the annual fee for a three-year PG program in government-run medical colleges in Gujarat is Rs 25,000, and for a five-year undergraduate program, Rs 15,000.
The companies involved in the privatization of these hospitals have also been accused of having close ties with the BJP government, with the Torrent Group purchasing electoral bonds worth Rs 184 crore between 2019 and 2024, and the Zydus Group giving bonds totaling Rs 29 crore to the BJP between 2022 and 2023. The privatization of these hospitals has raised concerns about the impact on public healthcare in Gujarat, particularly in rural areas where access to healthcare is already limited. The controversy surrounding the privatization of these hospitals highlights the need for greater transparency and accountability in the management of public healthcare facilities.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.